Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | ALPI | P09923 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8295626 | 0.82 | SLC7A5 (0.49) | SLC7A5NOS3NOS1NOS2 | |
| SCHEMBL16670314 | 0.82 | CIT (0.39) | SLC7A5TAAR1 | |
| SCHEMBL16670312 | 0.82 | CIT (0.39) | SLC7A5TAAR1 | |
| SCHEMBL7269254 | 0.80 | SLC7A5 (0.56) | SLC7A5FAAHALPIPKMPTGS1 | |
| SCHEMBL7438290 | 0.80 | SLC7A5 (0.56) | SLC7A5FAAHALPIPKMPTGS1 | |
| SCHEMBL20773131 | 0.79 | SLC7A5 (0.46) | SLC7A5FAAHNOS3NOS1NOS2 | |
| SCHEMBL20793245 | 0.79 | SLC7A5 (0.43) | SLC7A5FAAHNOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL6161681 | 0.78 | SLC7A5 (0.54) | SLC7A5FAAHALPIPKMPTGS1 | |
| Hydrochloric Acid SCHEMBL1126065 | 0.78 | SLC7A5 (0.54) | SLC7A5FAAHALPIPKMPTGS1 | |
| SCHEMBL20773133 | 0.78 | SLC7A5 (0.42) | SLC7A5FAAHNOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | SLC7A5 4282/4885FAAH 2377/4885NOS3 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.